Apoptosis and cancer

Clinical and Translational Oncology

Volumn 2, Issue 4, 2000, Pages 180-190

  del Peso, Luis ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Apoptosis; Bcl 2; Cancer; Caspases; Oncogenes; TNF; Tumor suppressor genes

Indexed keywords

EID: 84873657438     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/BF02979553     Document Type: Review

References (105)

1. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
2. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-354.
3. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
4. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
5. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
6. Thornberry NA, Lazebnik Y. Capases: enemies within. Science 1998; 281: 1312-1316.
7. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
8. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
9. Del Peso L, Núñez G. Linking extracellular survival signals and the apoptotic machinery. Curr Opin Neuro-biol 1998; 8: 613-618.
10. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
11. Hetts SW. To die or not to die. An overview of apopto-sis and its role in disease. JAMA 1998; 279: 300-307.
12. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984; 226: 1097-1099.
13. H on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 899-906.
14. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immu-noglobulin transcript resulting from the t(14;18) trans-location. Cell 1986; 47: 19-28.
15. Reed JC, Cuddy M, Slabiak T, Croce CM, Nowell PC. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature 1988; 336: 259-261.
16. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes hae-mopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
17. McDonnell TJ, Deanne N, Platt FM et al. Bcl-2 immu-noglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
18. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL-2 family and cell death. Blood 1996; 88: 386-401.
19. El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
20. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
21. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637-640.
22. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997; 389: 300-305.
23. Wu GS, Burns TF, McDonald ER 3rd et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-143.
24. Miyashita T, Krajewski S, Krajewska M et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9: 1799-1805.
25. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994; 54: 3131-3135.
26. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 281: 1317-1322.
27. Symonds H, Krall L, Remington L et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78: 703-711.
28. Stambolic V, Suzuki A, De la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
29. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salve-sen GS, Bredesen DE. The DCC gene product induces apoptosis by a mechanism requiring receptor proteoly-sis. Nature 1998; 395: 801-804.
30. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, De The H. PML induces a novel caspase-indepen-dent death process. Nat Genet 1998; 20: 259-265.
31. Wang ZG, Ruggero D, Ronchetti S et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20: 266-272.
32. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 1996; 93: 7950-7954.
33. Helbing CC, Veillette C, Riabowol K, Johnston RN, Gar-kavtsev I. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res 1997; 57: 1255-1258.
34. Shao N, Chai YL, Shyam E, Reddy P, Rao VN. Induction of apoptosis by the tumor suppressor protein BRCA1. Oncogene 1996; 13: 1-7.
35. Harkin DP, Bean JM, Miklos D et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 1999; 97: 575-586.
36. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59: 3333-3339.
37. Sard L, Accornero P, Tornielli S et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96: 8489-8492.
38. Tanaka N, Ishihara M, Kitagawa M et al. Cellular commitment to oncogene-induced transformation or apop-tosis is dependent on the transcription factor IRF-1. Cell 1994; 77: 829-839.
39. Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA. The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev 1995; 9: 2143-2156.
40. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyro-sine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-1947.
41. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-362.
42. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-4245.
43. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378.
44. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
45. Del Peso L, González-García M, Page C, Herrera R, Núñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
46. Cardone MH, Roy N, Stennicke HR et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
47. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96: 857-868.
48. Tang ED, Núñez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999; 274: 16741-16746.
49. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999; 401: 82-85.
50. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401: 86-90.
51. Bellacosa A, Testa JR, Staal SP, Tsichlis PN. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 1991; 254: 274-277.
52. Chang HW, Aoki M, Fruman D et al. Transformation of chicken cells by the gene encoding the catalytic subu-nit of PI 3-kinase. Science 1997; 276: 1848-1850.
53. Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84: 5034-5037.
54. Cheng JQ, Ruggeri B, Klein WM et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996; 93: 3636-3641
55. Cheng JQ, Godwin AK, Bellacosa A et al. AKT2, a putative oncogene encoding a member of a subfamily of pro-tein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci USA 1992; 89: 9267-9271.
56. Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102.
57. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and autoimmunity in Pten+/-mice. Science 1999; 285: 2122-2125.
58. Rampino N, Yamamoto H, Ionov Y et al. Somatic fra-meshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967-969.
59. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998; 9: 47-57.
60. Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthas-wamy HN, Owen-Schaub LB. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999; 285: 898-900.
61. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
62. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apopto-sis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 1992; 89: 7742-7746.
63. Qin XQ, Livingston DM, Kaelin WG Jr, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994; 91: 10918-10922.
64. Jiménez B, Arends M, Esteve P et al. Induction of apop-tosis in NIH3T3 cells after serum deprivation by ove-rexpression of rho-p21, a GTPase protein of the ras superfamily. Oncogene 1995; 10: 811-816.
65. Wang HG, Millan JA, Cox AD et al. R-Ras promotes apoptosis caused by growth factor deprivation via a Bcl-2 suppressible mechanism. J Cell Biol 1995; 129: 1103-1114.
66. Downward J. Ras signaling and apoptosis. Curr Opin Genet Dev 1998; 8: 49-54.
67. Fukasawa Y, Ishikura H, Takada A et al. Massive apopto-sis in infantile myofibromatosis. A putative mechanism of tumor regression. Am J Pathol 1994; 144: 480-485.
68. Preston GA, Lang JE, Maronpot RR, Barrett JC. Regulation of apoptosis by low serum in cells of different stages of neoplastic progression: enhanced susceptibility after loss of a senescence gene and decreased susceptibility after loss of a tumor suppressor gene. Cancer Res 1994; 54: 4214-4223.
69. Naik P, Karrim J, Hanahan D. The rise and fall of apop-tosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev 1996; 10: 2105-2116.
70. Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 1996; 56: 2998-3003.
71. Soengas MS, Alarcon RM, Yoshida H et al. Apaf-1 and cas-pase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999; 284: 156-159.
72. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-media-ted selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
73. Schmaltz C, Hardenbergh PH, Wells A, Fisher DE. Regulation of proliferation-survival decisions during tumor cell hypoxia. Mol Cell Biol 1998; 18: 2845-2854.
74. Stempien-Otero A, Karsan A, Cornejo CJ et al. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem 1999; 274: 8039-8045.
75. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.
76. Inbal B, Cohen O, Polak-Charcon S et al. DAP kinase links the control of apoptosis to metastasis. Nature 1997; 390: 180-184.
77. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
78. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
79. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
80. Gimmi CD, Morrison BW, Mainprice BA et al. Breast cancer-associated antigen, DF3/MUC1, induces apopto-sis of activated human T cells. Nat Med 1996; 2: 1367-1370.
81. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999; 5: 938-942.
82. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11: 121-139.
83. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151-157.
84. Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phe-notype. Blood 1995; 86: 1903-1910.
85. Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood 1997; 90: 1208-1216.
86. Liu R, Page C, Beidler DR, Wicha MS, Núñez G. Overex-pression of Bcl-XL promotes chemotheraphy resistance of mammary tumors in a syngeneic mouse model. Am J Path
87. Krajewski S, Blomqvist C, Franssila K et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast ade-nocarcinoma. Cancer Res 1995; 55: 4471-4478.
88. Tu Y, Renner S, Xu F et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998; 58: 256-262.
89. Campos L, Rouault JP, Sabido O et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
90. Hill ME, MacLennan KA, Cunningham DC et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lympho-ma Investigation Study. Blood 1996; 88: 1046-1051.
91. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lympho-mes de l'Adulte (GELA). Blood 1996; 87: 265-272.
92. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999; 5: 412-417.
93. Walczak H, Miller RE, Ariail K et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-indu-cing ligand in vivo. Nat Med 1999; 5: 157-163.
94. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Oku-mura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189: 1451-1460.
95. Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
96. Lamm GM, Christofori G. Impairment of survival factor function potentiates chemotherapy-induced apopto-sis in tumor cells. Cancer Res 1998; 58: 801-807.
97. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumo-rigenesis. Cancer Res 1996; 56: 4013-4020.
98. Bakker TR, Reed D, Renno T, Jongeneel CV. Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apopto-sis. Int J Cancer 1999; 80: 320-323.
99. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373-376.
100. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature 1998; 392: 296-300.
101. Newton K, Harris AW, Bath ML, Smith KGC, Strasser A. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J 1998; 17: 706-718.
102. Zornig M, Hueber AO, Evan G. p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol 1998; 8: 467-470.
103. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996; 13: 1511-1519.
104. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15: 6979-6990.
105. Green DR, McGahon A, Martin SJ. Regulation of apop-tosis by oncogenes. J Cell Biochem 1996; 60: 33-38.